Dognostic

Dognosis is a deep-tech healthcare and diagnostics company that digitizes and scales canine olfactory intelligence for early disease detection. Founded in 2023 and headquartered in Bengaluru, India, the company combines the extraordinary scent-detection capabilities of trained dogs with non-invasive brain-computer interfaces (BCI) and machine learning. Its flagship product, CancerWatch (formerly BreathEasy), is a non-invasive multi-cancer early detection (MCED) test that analyzes volatile organic compounds (VOCs) from a single 10-minute breath sample. Dognosis's proprietary platform includes DogSense, a custom-fitted canine EEG helmet, and DogOS, an AI software suite that translates canine neurobehavioral responses into quantitative disease risk scores. In April 2026, the company published a landmark Phase 2 clinical trial in the Journal of Clinical Oncology, demonstrating over 90% accuracy across seven major cancer types, including early-stage (I and II) cancers.